Litcius/Paper detail

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

Shuyun Rao, Xiaochun Yang, Kazufumi Ohshiro, Sobia Zaidi, Zhanhuai Wang, Kirti Shetty, Xiyan Xiang, Md. Imtaiyaz Hassan, Taj Mohammad, Patricia S. Latham, Bao‐Ngoc Nguyen, Linda L. Wong, Herbert Yu, Yousef Al‐Abed, Bibhuti Mishra, Michèle Vacca, Gareth Guenigault, Michael Allison, Antonio Vidal‐Puig, Jihane N. Benhammou, Marcus Alvarez, Päivi Pajukanta, Joseph R. Pisegna, Lopa Mishra

2021Science Translational Medicine48 citationsDOIOpen Access PDF

Abstract

expression. Thus, our data indicate that SPTBN1 represents a potential target for therapeutic intervention in NASH and liver cancer.

Topics & Concepts

LipogenesisLiver cancerCancer researchSterol regulatory element-binding proteinFatty liverFibrosisCancerSteatosisEndocrinologyInternal medicineNonalcoholic fatty liver diseaseSteatohepatitisBiologyMedicineLipid metabolismDiseaseCholesterolSterolLiver Disease Diagnosis and TreatmentCancer, Lipids, and MetabolismLipid metabolism and disorders
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development | Litcius